Postmarketing Study End Of Usefulness Must Be Confirmed By FDA
Executive Summary
Industry must continue to submit status reports on terminated postmarketing drug studies until FDA concurs the studies will provide no more useful information, under a proposed revision to postmarketing study status annual reporting regs.
You may also be interested in...
FDA Phase IV Website Planned For October 2001; Final Tracking Rule Issued
FDA plans to launch a website on the status of pharmaceutical company Phase IV commitments by Oct. 1, 2001.
FDA Phase IV Website Planned For October 2001; Final Tracking Rule Issued
FDA plans to launch a website on the status of pharmaceutical company Phase IV commitments by Oct. 1, 2001.
Sponsors' Failure To Complete Phase IV Studies Should Draw Penalties - HRG
Public Citizen's Health Research Group is calling for FDA to seek authority to levy money penalties in cases where sponsors have failed to complete postmarketing studies requested by the agency.